Find us on:


Research Type
Reported as
Publication Type
Sort By
Total: 167
Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Research Type Human Reported as Case Report/Series/Restrospective Study Date November 19, 2019 Authors Olli Polo, Pia Pesonen, Essi Tuominen Institution Unesta Clinic and Research Center Disease CFS
BACKGROUND: Myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS) is a common medical condition that limits physical and cognitive functions, with no known effective medical treatment. METHODS: We report on the safety and effectiveness data accumulated in clinical practice when treating ME/CFS with low-dose naltrexone (LDN, 3.0 – 4.5 mg/day). The medical records from 218 patients who received ar diagnosis of ME/CFS and LDN treatment during 2010–2014 were retrospectively analyzed...
Low-dose naltrexone safe, effective for neuropathic corneal pain
Research Type Human Reported as Case Report/Series/Restrospective Study Date October 25, 2019 Authors Gabriella Dieckmann, M. Cuneyt Ozmen, Ryan Engert, Melina Morkin, Pedram Hamrah Institution Tufts University Disease Neuropathic Corneal Pain
"Treatment with low-dose naltrexone resulted in improvements in pain and quality of life scores without serious side effects among patients with neuropathic corneal pain," according to a presenter at the American Academy of Ophthalmology annual meeting (Oct 11-15, 2019; San Francisco). “Neuropathic corneal pain is a disease that causes nerve damage and results in pain or discomfort,” Gabriela Dieckmann, MD, from the department of ophthalmology at Tufts Medical Center, said. “Low-dose nalt...
Changes in the consumption of antiepileptics and psychotropic medicines after starting low dose naltrexone: A nation-wide register-based controlled before-after study
Research Type Human Reported as Case Report/Series/Restrospective Study Date October 21, 2019 Authors Guttorm Raknes, Lars Småbrekke Institution University Hospital of North Norway, Raknes Research, UiT - The Arctic University of Norway Disease Psychiatric Conditions
In this controlled before-after study based on data from the Norwegian Prescription Database, we examine whether starting off-label use of Low Dose Naltrexone (LDN) is followed by changes in the consumption of psychotropic medicines including antiepileptics. Patients that collected LDN for the first time in 2013 (N = 11247) were included and stratified into three groups based on LDN exposure. We compared differences in means of cumulative number of defined daily doses (DDD) as well as change...
Low-dose naltrexone-induced remission in Hailey–Hailey disease maintained in remission with topical combination of ketamine and diphenhydramine
Research Type Human Reported as Case Report/Series/Restrospective Study Date September 24, 2019 Authors Sidharth Sonthalia, Mahima Agrawal, Ankur Talwar, Mohamad Goldust Institution Mazandaran University of Medical Sciences; HIMS Institute, LHMC and Associated Hospitals, Skinnocence Skin Clinic and Research Centre Disease Hailey-Hailey
Recent anecdotal evidence suggests that oral low-dose naltrexone (LDN) is effective for Hailey–Hailey disease (HHD) but suffers the limitation of immediate relapse following cessation of the medication. With lack of safety data on long-term administration of LDN, we explored the utility of a topical diphenhydramine/ketamine (DK) cream in maintaining the remission achieved with LDN. A 42-year-old male with treatment-refractory HHD remitted with 5 mg naltrexone/day but relapsed on stopping the d...
A Retrospective Review of Patients Prescribed Low Dose Naltrexone for Chronic Pain at a Single Institution
Research Type Human Reported as Case Report/Series/Restrospective Study Date September 20, 2019 Authors Anne McKenzie-Brown, Ezihe Agwu, Vinita Singh Institution Emory University School of Medicine Disease Chronic Pain
INTRODUCTION: Safe and effective alternatives are needed to long-term opioids for the treatment of chronic pain.(1) Low dose naltrexone (LDN) has unique analgesic properties with few side effects. LDN temporarily blocks intrinsic opioid receptors with rebound increase in beta endorphin and methionine enkephalin (Met-Enkephalin) receptors. LDN is also an immune modulator, working at the level of the glial cell as a toll like receptor 4 (TLR4) antagonist.(2) The most commonly reported dose related...
Hailey-Hailey disease treated successfully with naltrexone and magnesium.
Research Type Human Reported as Case Report/Series/Restrospective Study Date August 29, 2019 Authors Ali Alajmi, Abdulhadi Jfri, Audrey Lovett Institution McGill University Health Centre Disease Hailey-Hailey
Hailey-Hailey disease (HHD), or benign familial pemphigus, is an autosomal dominant genodermatosis that usually presents between the second and fourth decades of life as painful blisters and erosions in the intertriginous areas. It is characterized by a remitting, relapsing course, and recurrent episodes of superinfection. HHD is caused by mutations in the ATP2C1 gene. Although HHD is not life threatening, it has a significant negative impact on patient quality of life. Many treatments exist, b...
Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias?
Research Type Human Reported as Opinion Date August 15, 2019 Authors Violeta Duarte Tortelly, Taynara de Mattos Barreto, Larissa Starling de Albuquerque Fernandes, Bruno Eduardo Morais Nunes, Daniel Fermandes Melo Institution State University of Rio de Janeiro, Marcilio Dias Naval Hospital Disease Alopecia
Naltrexone is a competitive antagonist of μ, k and γ opioid receptors, used for treatment of alcoholism and opioid addiction. Low-dose naltrexone (LDN) is defined as daily doses ranging from 1mg to 5mg. This is purported to have a paradoxical effect that leads to an increase in endogenous opioids, including beta-endorphins, which have anti-inflammatory properties. These mechanisms may also justify their possible role in the treatment of inflammatory conditions. The aim of this article is to di...
Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy
Research Type Human Animal Lab (in-vitro) Reported as Review Date August 09, 2019 Authors Ruizhe Wang, Yi Zhang, Fengping Shan Institution China Medical University Disease Cancer (general)
 Endogenous opioids are neuro-peptides with multifunctional properties. Historically, opioids are used to mediate pain; however, excess opiate consumption can lead to addiction. One endogenous opioid, methionine enkephalin (MENK), was reported to modulate cell growth, MENK was identified as an opioid growth factor (OGF) that interacts with the OGF receptor (OGFr) and regulates cell proliferation. Further, opioid antagonists, including naltrexone and naloxone are widely used to reverse drug and ...
Naltrexone for the Treatment of Darier and Hailey-Hailey Diseases.
Research Type Human Reported as Review Date July 01, 2019 Authors A Jfri, IV Litvinov, E Netchiporouk Institution McGill University Disease Darier Disease, Hailey-Hailey
Darier (DD) and Hailey-Hailey (HHD) diseases are both genodermatoses caused by defective calcium transport and homeostasis. DD is caused by a mutation of the ATPA2A gene and HHD by a mutation of the ATP2C1 gene. Clinically, the former is characterized by itchy, painful macerations with red-brownish papules in a seborrheic distribution; the latter manifests with painful blisters that rupture, leaving erosions in intertriginous areas. Treatment options for both conditions are limited and include t...
Low-dose naltrexone: a unique treatment for amyopathic dermatomyositis
Research Type Human Reported as Case Report/Series/Restrospective Study Date June 01, 2019 Authors Albert P. Manudhane, Kory P. Schrom, Harib H. Ezaldein, James A. Armile Institution Brown University Warren Alpert Medical School, University Hospitals Cleveland Medical Center, Case Western Reserve University, Lake Erie College of Osteopathic Medicine Disease Amyopathic Dermatomyositis
Gottron papules, a heliotrope rash, scalp and extremity erythema, pruritus, and fatigue are the characteristic signs and symptoms of amyopathic dermatomyositis (ADM). Amyopathic dermatomyositis is considered a distinct entity from dermatomyositis (DM) because the characteristic muscle weakness and muscle enzyme elevations of DM are absent in ADM. With respects to treatment, ADM treatments have traditionally included topical corticosteroids and/or systemic immunosuppressants and immunomodulators....